olanzapine / Generic mfg. - LARVOL DELTA

Primary analysis of the phase 3 randomized trial of selinexor and lenalidomide versus lenalidomide alone as maintenance therapy post autologous stem cell transplant for patients with newly diagnosed multiple myeloma (ALLG MM23; SEALAND) (ASH 2025) - P3 | "Introduction:Selinexor (S) is an oral selective exportin 1 inhibitor approved in relapsed multiple myeloma (MM) incombination with bortezomib (V) and dexamethasone (d)...Patients received ondansetron 8mg immediately prior to, and 8-hours following each S dose.Additional ondansetron and low-dose olanzapine were used as required for break-through nausea andvomiting...In this randomized phase III study, the addition of low-dose S to R maintenance following ASCT did notresult in a significant PFS benefit compared to R alone in NDMM. Although a higher CR rate was observedwith SR, this came at the cost of increased toxicity, including more infections, cytopenias andgastrointestinal AEs. Quality of life, as assessed by EORTC QLQ-C30 and MY20, was comparable betweenarms."

Clinical • P3 data • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Thrombocytopenia • Transplantation • XPO1

The SCOPE trial: A phase 2 Study of selinexor in combination with pomalidomide and dexamethasone for patients with relapsed and/or refractory multiple myeloma (ASH 2025) - "In combination with dexamethasone, selinexor is currently approved at 80 mgtwice a week dose, and in combination with bortezomib plus dexamethasone, it is approved at 100 mgonce weekly dose for patients with relapsed and/or refractory multiple myeloma (RRMM)...MethodsThe SCOPE trial is an investigator-initiated, single arm, phase 2 study that assessed the efficacy andsafety of selinexor (S), 60 mg orally (PO) weekly, pomalidomide (P), 4 mg PO, days 1-21 anddexamethasone (d), 40 mg PO, weekly in 28-day cycles given for a fixed duration (total 18 cycles ) inpatients who were exposed to up to 2 prior lines of antimyeloma therapy, at least one of which includedboth a proteasome inhibitor and the immunomodulatory agent, lenalidomide. Olanzapine, along with a5-HT3 antagonist comprised the mandatory anti-emetic prophylactic regimen...Notably, 64% of patients had previously been exposed to the anti-CD38monoclonal antibody, daratumumab, and 11% of patients were..."

Clinical • Combination therapy • P2 data • Anorexia • Infectious Disease • Multiple Myeloma • Neutropenia • Thrombocytopenia

Psychiatric Presentation of Hereditary Coproporphyria with Coproporphyrinogen Oxidase Gene Mutation c.734 C>T: A Case Report. (PubMed, Noro Psikiyatr Ars) - "After initiating treatment with valproic acid and olanzapine for a presumptive diagnosis of bipolar I disorder, a manic episode with psychotic features, the patient's general medical condition worsened...Cases that initially present with symptoms specific to a single system can pose diagnostic challenges. In our case report, we aimed to present the psychiatric onset of hereditary coproporphyria, a rare subtype of porphyria known for its potentially fatal attacks when untreated."

Journal • Bipolar Disorder • CNS Disorders • Genetic Disorders • Hematological Disorders • Metabolic Disorders • Psychiatry • CPOX

Efficacy of anti-emetic therapy in highly emetogenic chemotherapy-induced nausea and vomiting in breast cancer patients: A prospective observational study from a tertiary care centre (ESMO Asia 2025) - "This study evaluates whether low-cost olanzapine offers comparable QOL preservation in a South Indian cohort. This prospective observational study (June 2022–December 2023) at a single South Indian center included 113 breast cancer patients receiving highly emetogenic chemotherapy (Adriamycin/Epirubicin + Cyclophosphamide). Olanzapine maintained QOL and controlled nausea comparably to NK-1 RAs in breast cancer patients on HEC, though NK-1 RAs achieved higher CR rates for CINV. Given its lower cost and steroid-sparing potential, olanzapine is a viable alternative in resource-limited settings for preserving QOL while providing reasonable emesis control."

CINV • Clinical • Observational data • Breast Cancer • Chemotherapy-Induced Nausea and Vomiting • Oncology • Solid Tumor

A prospective randomized, double-blind controlled trial of olanzapine versus placebo in addition to ondansetron plus dexamethasone as antiemetic prophylaxis in patients receiving moderately emetogenic chemotherapy (ESMO Asia 2025) - "Given the comparable efficacy of olanzapine, this study evaluated the effectiveness of 5 mg olanzapine (OLN) in combination with ondansetron and dexamethasone in preventing chemotherapy-induced nausea and vomiting (CINV) in patients undergoing MEC. This double-blind, randomized controlled trial included patients receiving their first cycle of oxaliplatin-, carboplatin-, or irinotecan-based chemotherapy. Olanzapine (5 mg) combined with ondansetron and dexamethasone significantly improved prevention of CINV in patients receiving MEC. This regimen may serve as a new standard of care."

Clinical • Chemotherapy-Induced Nausea and Vomiting • Oncology

Low dose olanzapine versus megestrol acetate for treatment of loss of appetite in patients with locally advanced or metastatic gastric, hepato-pancreatico-biliary and lung cancer (ESMO Asia 2025) - "Low dose Olanzapine demonstrated comparable efficacy to Megestrol Acetate in promoting weight gain and appetite in vulnerable cancer patients undergoing chemotherapy. With its favorable tolerability, additional antiemetic utility, convenient once daily dosing and substantial lower cost, low dose Olanzapine may be preferred over Megestrol Acetate for management of CAS in clinical practice."

Clinical • Metastases • Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor

Impact of enhanced antiemetic prophylaxis including atypical antipsychotics in zolbetuximab-containing chemotherapy: A retrospective study (ESMO Asia 2025) - "Additionally, 14 pts received prophylactic olanzapine on the evening of day -1, 1 on the morning of day 1, and 2 received asenapine on day -1. The addition of atypical antipsychotics may help relieve zolbetuximab-induced nausea, with a notably low incidence of grade 3 events and good tolerability. However, as nausea still occurred in a substantial proportion of patients, particularly those at higher risk, further preventive strategies should be considered."

Retrospective data • Gastric Cancer • Oncology • Solid Tumor

Efficacy of olanzapine in enhancing weight gain in advanced cancer patients receiving chemotherapy: A randomized placebo-controlled trial (ESMO Asia 2025) - "Olanzapine 5 mg/day showed a non-significant trend toward improved weight, appetite, and nutritional status in advanced cancer patients on chemotherapy. While the primary endpoint was unmet, olanzapine appears safe and potentially beneficial for cachexia management. Larger studies are warranted."

Clinical • Metastases • Gastrointestinal Cancer • Oncology

Impact of menopausal status and TACR1 polymorphisms on the risk of chemotherapy-induced nausea and vomiting in female breast cancer patients: A post hoc analysis of the PATROL-II trial (ESMO Asia 2025) - P2 | "The purpose of this study was to clarify the impact of menopausal status and TACR1 polymorphisms on CINV. This study was a post hoc analysis of the multicenter phase II trial, "PATROL-II trial" which evaluated the efficacy and safety of palonosetron, aprepitant, and olanzapine... Menopausal status and TACR1 rs2111375 polymorphism may be associated with CINV."

CINV • Clinical • Retrospective data • Breast Cancer • Chemotherapy-Induced Nausea and Vomiting • Oncology • Solid Tumor • TACR1

Multi-centre experience of tolerability of Zolbetuximab (Zolb) in combination with chemo for advanced gastroesophageal adenocarcinoma (GEA) in Singapore (SGP) (ESMO Asia 2025) - "Chemo backbones: SOX/CAPOX (36%), mFOLFOX6 (36%), FP + i.p Paclitaxel (14%), mFOLFIRI (9%) and mFOLFOX6 + Nivolumab (5%)...From cycle 2, 10/18 pts (59%) had infusion rates lengthened; 5/18 pts (28%) received extra antiemetics (4 olanzapine, 1 lorazepam)... IRRs with Zolb were manageable and lower than phase III studies due to triplet antiemetic prophylaxis in cycle 1. Adjusting Zolb infusion rate and antiemetics further reduced IRRs. Zolb plus chemo had manageable AEs, supporting its use in SGP."

Clinical • Combination therapy • Metastases • Esophageal Adenocarcinoma • Esophageal Cancer • Oncology • Solid Tumor

Second-generation antipsychotics - Cardiac ion channel modulation and QT interval disturbances: A review. (PubMed, Biomol Biomed) - "A narrative literature review was conducted using PubMed, Web of Science, and Google Scholar, without year restrictions, focusing on English-language experimental and clinical studies related to clozapine, olanzapine, risperidone, quetiapine, and ziprasidone. Notably, the observed variability in the ratio of half-maximal inhibitory concentration to maximum free plasma concentration (IC₅₀/Cmax,free) reflects its dependence on both the degree of hERG inhibition and the pharmacokinetic properties specific to each SGA. Additionally, several SGAs affect other potassium, sodium, and calcium currents, which may either mitigate or exacerbate the consequences of IKr inhibition. In conclusion, QT interval prolongation associated with SGAs is primarily driven by hERG potassium channel blockade, although the degree of this effect varies significantly among different agents. This variability highlights the necessity for electrocardiogram (ECG) monitoring and..."

Journal • Review • Cardiovascular • CNS Disorders • Psychiatry

Akkermansia muciniphila Alleviates Olanzapine-Induced Hepatic Steatosis via the Gut Microbiota-IGFBP2/APOA1-Liver Axis. (PubMed, Microb Biotechnol) - "Functional validation demonstrated that overexpression of IGFBP2 and APOA1 alleviated olanzapine-induced hepatic steatosis in both cellular and animal models. These findings suggest that A. muciniphila exerts hepatoprotective effects via the gut microbiota-IGFBP2/APOA1-liver axis, offering a potential microbiota-targeted strategy to mitigate olanzapine-induced metabolic dysfunction."

Journal • CNS Disorders • Hepatology • Liver Failure • Metabolic Disorders • APOA1 • IGFBP2

A multi-practice quality initiative evaluating antiemetic use in metastatic breast cancer patients treated with trastuzumab deruxtecan-nxki (T-DXd) (SABCS 2025) - "Background: As of January 2023, the National Comprehensive Cancer Network (NCCN) guidelines recommend using combinations of 5HT3, NK1, olanzapine (O), and dexamethasone (DEX) drugs as prophylaxis with highly emetic therapies, including fam-trastuzumab deruxtecan-nxki (T-DXd). This multi-practice quality initiative led to improved antiemetic utilization that is in line with NCCN guidelines in HER2+ and HER2-low mBC pts treated with T-DXd. These findings highlight that with established guidelines, oncology practices can benefit from regularly evaluating their own data to assess their treatment compared to the latest clinical standards."

Clinical • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Disproportionality and time-to-onset analyses of drug-induced weight gain using the Japanese Adverse Drug Event Report database. (PubMed, Drug Discov Ther) - "Pregabalin showed the earliest median onset at 19 days (early failure), followed by olanzapine and risperidone at 1-2 months, pioglitazone at 2 months, and clozapine at 6 months, all classified as random failure types. These findings underscore the need for careful weight monitoring during treatment, particularly early with pregabalin and long-term with clozapine and pioglitazone. Prospective studies are warranted to clarify causal relationships and clinical implications."

Adverse events • Journal • Cardiovascular • CNS Disorders • Genetic Disorders • Metabolic Disorders • Obesity

Comment: Olanzapine Versus Quetiapine: Corrected QT Changes in Critically Ill Patients. (PubMed, Ann Pharmacother) - No abstract available

Journal

Reply: Olanzapine Versus Quetiapine: Corrected QT Changes in Critically Ill Patients. (PubMed, Ann Pharmacother) - No abstract available

Journal

Drug-induced polycystic ovary syndrome: a real-world pharmacovigilance study based on the FAERS database. (PubMed, Front Endocrinol (Lausanne)) - "The median time to onset for the top three drugs with the highest signal frequency was as follows: Olanzapine (155.5 days), Quetiapine (335 days), and Valproic acid (905 days). The drugs identified are primarily associated with the nervous system, followed by respiratory system medications and other types of drugs. These findings provide new warning evidence and references for clinical drug safety, suggesting that enhanced monitoring of female patients should be implemented when prescribing such drugs."

Adverse events • Journal • Real-world evidence • CNS Disorders • Polycystic Ovary Syndrome

Semaglutide and Early-Stage Metabolic Abnormalities in Individuals With Schizophrenia Spectrum Disorders: A Randomized Clinical Trial. (PubMed, JAMA Psychiatry) - P4 | "To evaluate the efficacy of adjunctive semaglutide on glycemic control, weight-associated outcomes, and cardiometabolic risk factors in individuals with schizophrenia spectrum disorders receiving clozapine or olanzapine and exhibiting early glycemic abnormalities. These findings support the use of GLP-1RAs as a potential early intervention strategy to reduce cardiometabolic risk in this vulnerable population. ClinicalTrials.gov Identifier: NCT04892199."

Clinical • Journal • Cardiovascular • CNS Disorders • Genetic Disorders • Metabolic Disorders • Obesity • Psychiatry • Schizophrenia • Type 2 Diabetes Mellitus

The Effect of Semaglutide With Lifestyle Intervention on the Physical Health of Patients Treated With Antipsychotic Drugs in a Secure Mental Health Setting: Protocol for an Uncontrolled Pretest-Posttest Pilot Mixed Methods Study. (PubMed, JMIR Res Protoc) - "Antipsychotic-induced weight gain is a common side effect of antipsychotic drug treatment, particularly with second-generation medications such as clozapine and olanzapine. Implementation changes that could improve the acceptability of and adherence to the intervention will be explored. This research should be beneficial for patients with severe mental illness who are living with obesity and are residing in a secure setting as the findings may ultimately reduce the mortality risk in this patient group."

Journal • CNS Disorders • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity

Prescribing Patterns and Adverse Reactions of Antipsychotics in a North Indian Psychiatry Outpatient Department. (PubMed, Cureus) - "It is necessary to justify the antipsychotic drug prescribing pattern. By evaluating prescription habits, one may determine the incidence of pharmacovigilance and polytherapy, which helps to minimize and avoid adverse medication responses."

Journal • Bipolar Disorder • CNS Disorders • Mental Retardation • Movement Disorders • Psychiatry • Schizophrenia

Case Report: Metabolic, inflammatory, and neurological improvements after a ketogenic diet in a woman with treatment-resistant schizophrenia and metabolic syndrome. (PubMed, Front Psychiatry) - "These results are congruent with emerging data suggesting various health benefits of KD for people with schizophrenia, and we report for the first time its impact in TRS with long-term use of antipsychotic medications (clozapine, olanzapine) that contribute to metabolic syndrome, parkinsonian-like symptoms, and cardiac risk. We also suggest that well-controlled clinical trials longer than 5 weeks and with consistent ketosis are needed. Additionally, lower calories or a higher ratio of fat to combined protein and carbohydrate may be necessary to maintain ketosis for individuals with metabolic dysfunction who are taking antipsychotic medication."

Clinical • Journal • CNS Disorders • Inflammation • Metabolic Disorders • Movement Disorders • Parkinson's Disease • Psychiatry • Schizophrenia

What is the best approach for parenteral sedation to manage severe acute behavioral disturbance in the emergency department? (PubMed, Clin Toxicol (Phila)) - "We recommend droperidol, or olanzapine where droperidol is unavailable, as the preferred first-line parenteral agent, due to strong evidence of effectiveness and safety...We do not routinely recommend benzodiazepines, such as midazolam, except for treating specific causes of agitation which respond well to benzodiazepines, such as alcohol withdrawal or stimulant intoxication...We do not routinely recommend benzodiazepines as first-line therapy, unless specifically treating a condition likely to benefit from benzodiazepines, such as alcohol (or sedative hypnotic) withdrawal or stimulant intoxication. We do not recommend combination therapy (antipsychotic and benzodiazepines)."

Journal • Anesthesia • CNS Disorders • Mental Retardation

Dopaminergic tone inhibits spontaneous glutamate release and augments homeostatic synaptic plasticity. (PubMed, Mol Psychiatry) - "Notably, chronic antagonism of both D1 and D2 receptors using selective antagonists, as well as long-term treatment with first- and second-generation antipsychotics haloperidol, chlorpromazine, olanzapine, clozapine, and aripiprazole, promoted robust synaptic upscaling. These findings reveal a novel mechanism of action for antipsychotic medications and suggest that antipsychotics do not solely act on counteracting hyperdopaminergia, but also tune glutamatergic neurotransmission by activating homeostatic plasticity mechanisms."

Journal • CNS Disorders

Improving the Appropriate Prescribing of Olanzapine for Chemotherapy-Induced Nausea and Vomiting: A Quality Improvement Initiative for the Outpatient Oncology Practice. (PubMed, J Adv Pract Oncol) - "Audit data obtained following the implementation of the QI project revealed a statistically significant improvement, which supported the hypothesis that providing education based on the PDSA model is an effective method to improve the compliance rate of appropriate olanzapine prescribing for CINV in patients receiving HEC. The result reflects the growing body of evidence confirming the validity of the PDSA model."

CINV • Journal • Chemotherapy-Induced Nausea and Vomiting • Oncology

A Study of Olanzapine in Participants With Bipolar Disorder. (clinicaltrials.gov) - P=N/A | N=3000 | Recruiting | Sponsor: Boryung Pharmaceutical Co., Ltd

New trial • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry